Infliximab as treatment of severe enteropathy in a patient with common variable immunodeficiency and cytomegalovirus infection

Gastroenterol Hepatol. 2018 Mar;41(3):163-164. doi: 10.1016/j.gastrohep.2017.03.002. Epub 2017 May 2.

[Article in English, Spanish]

Authors

Janire Prieto Elordui¹, Paz Arreba Gonzalez², Jone Ortiz de Zarate Sagastagoitia², Laura Deiss Pascual², Sonia Blanco Sampascual², Amaia Baranda Martín², Angel Calderón García², Carmen Muñoz Villafranca²

Affiliations

¹ Servicio de Aparato Digestivo, Hospital Universitario de Basurto, Bilbao, Vizcaya, España. Electronic address: janire.prietoelordui@osakidetza.net.
² Servicio de Aparato Digestivo, Hospital Universitario de Basurto, Bilbao, Vizcaya, España.

PMID: 28476306
DOI: 10.1016/j.gastrohep.2017.03.002

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Common Variable Immunodeficiency / complications*
Cytomegalovirus Infections / complications*
Female
Gastrointestinal Agents / therapeutic use*
Humans
Infliximab / therapeutic use*
Intestinal Diseases / drug therapy*
Intestinal Diseases / etiology*
Severity of Illness Index

Substances

Gastrointestinal Agents
Infliximab